This site is intended for US residents 18 years of age or older.
Text size
Text size

Welcome to Spark Therapeutics Generation Patient ServicesSM

Supporting patients with diagnosed inherited retinal diseases (IRDs) due to mutations in both copies of the RPE65 gene, their caregivers, and the healthcare professionals that treat them

We know that getting diagnosed with an IRD can be overwhelming. That’s why our goal at Spark Generation Patient Services is to support patients that have been diagnosed with an IRD due to mutations in both copies of the RPE65 gene every step of the way, from confirmed diagnosis through postsurgery follow up.

Spark Therapeutics Generation
Patient Services Team Member

For patients with a genetically diagnosed inherited retinal disease due to mutations in both copies of the RPE65 who are eligible for treatment with LUXTURNA® (voretigene neparvovec-rzyl), Generation Patient Services provides the ongoing support, financial information, and outreach resources you need most.

Spark Therapeutics Generation
Patient Services Team Member

Patient support services:
Supporting you along the way

Your support team is dedicated to each patient and available to help you on your LUXTURNA treatment journey.

Spark Therapeutics
Generation Patient Services Team

Financial resources:
Navigating all the details

Work with your team to understand billing and insurance coverage as well as your eligibility for financial assistance resources.

Photographs are not of
actual patients or caregivers

Resources:
Connecting you to info you can use

Access information, forms, and patient groups you need when you need them.

You keep us driven

We understand that living with a genetic disease can be challenging for patients and their caregivers. Your determination—and the determination of others like you—motivates the work that we do. Here at Spark® Therapeutics, we take a patient-centric approach to our research and support services.

Our pillars of commitment to you:

  • We partner with you for a more collaborative experience.
  • We provide support that is clear, caring, and customized.
  • We prioritize you in everything that we do.

Contact us now

Photographs are not of actual patients or caregivers

Participation in Spark Therapeutics Generation Patient Services is voluntary and is not required to get treatment with LUXTURNA. You may choose to participate in all, some, or none of the services offered. Participating or deciding not to participate in these services will have no effect on your ability to get treatment or the nature of your treatment or care. Generation Patient Services does not provide medical advice. You should always rely on the direction of your healthcare professional for treatment and care.

US Full Prescribing Information

IMPORTANT SAFETY INFORMATION FOR LUXTURNA (voretigene neparvovec-rzyl)

The following serious side effects may occur during or after the administration of LUXTURNA:

  • Eye infections, including a serious infection inside of the eye called endophthalmitis, that may lead to blindness.
  • Permanent decline in visual acuity, or the sharpness of central vision.
  • Changes in the retina (the thin layer of tissue in the back of the eye) that can lead to vision loss including:
    • development of a hole, thinning, or loss of function of the retina, separation of the layers in the center of the retina, loss of retinal cells and the choroid (the layer of blood vessels that lines the back of the eye), or bleeding in the retina.
    • breaks in or wrinkling on the surface of the retina or detachment of the retina.
  • Increased pressure inside of the eye. You should follow-up with your healthcare professional as instructed to detect and treat any increased pressure in the eye as this may cause blindness.
  • Expansion of the air bubble formed in the eye after administration of LUXTURNA. You should avoid air travel, travel to high elevations, or scuba diving until your healthcare professional has told you that the air bubble formed in the eye following administration of LUXTURNA has disappeared. Engaging in these activities while the air bubble is present can cause permanent vision loss.
  • Formation or worsening of cataract (clouding of the lens inside of the eye).

Tell your healthcare professional right away if you have any of the following symptoms of these serious side effects:

  • Seeing floaters (specks that float about in your field of vision)
  • Pain in the eye
  • Any change in vision including decreased vision or blurred vision
  • Seeing flashes of light

The following are the most common side effects that may occur with LUXTURNA:

  • Redness of the eye
  • Cataract (clouding of the lens inside of the eye)
  • Increased pressure inside of the eye
  • Breaks in the retina
  • Dellen (thinning of the clear layer in the front of the eye)
  • Development of a hole in the center of the retina
  • Subretinal deposits (deposits under the retina)
  • Eye swelling, irritation or pain
  • Wrinkling on the surface of the center of the retina

Treatment with LUXTURNA is not recommended for patients younger than 12 months of age because the retina is still growing, which may affect how LUXTURNA works.

Because small quantities of LUXTURNA may be in your tears for a short period of time, for the first 7 days after administration of LUXTURNA, place any waste material from dressings, tears and nasal secretions in sealed bags prior to disposal.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to Spark® Therapeutics at 1-855-SPARKTX (1-855-772-7589).

This information does not take the place of talking to your healthcare professional about your medical condition or treatment. If you have questions about LUXTURNA after reading this information, ask your healthcare professional.

Please see the US Full Prescribing Information for LUXTURNA.

INDICATION

LUXTURNA (voretigene neparvovec-rzyl) is a prescription gene therapy product used for the treatment of patients with inherited retinal disease due to mutations in both copies of the RPE65 gene, which can only be confirmed through genetic testing.

Show more

Accessibility policy

Throughout the creation of this website, we followed accessibility guidelines established by the World Wide Web Consortium (W3C®), an international group that develops website standards. Sites that don’t meet these guidelines can be challenging, or even unusable, for people with low vision. To avoid that possibility, we relied on W3C principles to guide each step, and to make this site accessible to all of our visitors.

Adjust the setting of the site for easier reading.

HIGH CONTRAST
Font size
AA
Line height